BioCryst Pharmaceuticals has not announced the completion date for the sale of its European Berotralstat business [1]. The company stated in August 2023 that it had initiated a process to explore strategic alternatives for its European Berotralstat business, which includes exploring options such as a divestiture [1].
What does Berotralstat treat?
Berotralstat, marketed as Orladeyo in Europe, is a medication used for the prophylactic treatment of hereditary angioedema (HAE) attacks in adult and adolescent patients [2]. HAE is a rare genetic disorder characterized by recurrent episodes of swelling [3].
Why is BioCryst selling its European Berotralstat business?
BioCryst's decision to explore strategic alternatives for its European Berotralstat business is part of a broader strategy to focus on its U.S. commercial operations and advance its pipeline programs [1]. The company aims to maximize the value of Orladeyo in Europe through a separate transaction while concentrating resources on its most promising opportunities [1].
When might a sale be completed?
No specific timeline has been provided for the completion of any potential sale of BioCryst's European Berotralstat business [1]. The company has indicated that the process is ongoing and that there can be no certainty that any transaction will occur [1].
Who are the potential buyers for Orladeyo in Europe?
The potential buyers for BioCryst's European Berotralstat business have not been publicly disclosed [1]. BioCryst has engaged financial advisors to assist with this strategic review [1].
What is the status of Orladeyo in other regions?
In the United States, Berotralstat is approved and marketed by BioCryst as Orladeyo for the chronic management of HAE in patients 12 years and older [4]. BioCryst retains all rights to Berotralstat in the United States and all other territories outside of Europe [1].
How does Berotralstat work?
Berotralstat is an oral, once-daily plasma kallikrein inhibitor [2][4]. By inhibiting plasma kallikrein, it helps to prevent the overproduction of bradykinin, a substance that contributes to the swelling associated with HAE attacks [3][4].
What are the current sales of Orladeyo in Europe?
Sales figures for Orladeyo specifically in Europe have not been detailed in BioCryst's most recent announcements regarding the strategic review [1]. The company has previously reported global net product revenue for Orladeyo, which includes both U.S. and European sales [1].
---
Sources:
[1] https://www.biocryst.com/news/press-release-details/2023/BioCryst-Announces-Initiation-of-Strategic-Review-of-European-Berotralstat-Business/
[2] https://www.ema.europa.eu/en/medicines/human/EPAR/orladeyo
[3] https://www.rarediseases.org/rare-diseases/hereditary-angioedema
[4] https://www.biocryst.com/patients/orladeyo/